What is the role of ketorolac (Toradol) injection in canine pain management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Ketorolac injection is a recommended option for short-term pain management in dogs, typically administered at 0.3-0.5 mg/kg intravenously or intramuscularly once daily for no more than 3 consecutive days, as it provides effective analgesia with a relatively favorable safety profile, as supported by studies such as 1 and 2.

Key Considerations

  • The medication works by inhibiting cyclooxygenase enzymes to reduce inflammation and provide analgesia, making it useful for acute post-surgical pain or traumatic injuries.
  • However, ketorolac should not be used long-term due to potential side effects including gastrointestinal ulceration, kidney damage, and bleeding disorders.
  • It should be avoided in dogs with pre-existing kidney disease, gastrointestinal issues, bleeding disorders, or those taking other NSAIDs or corticosteroids.
  • Veterinary supervision is essential when using ketorolac, as it is not FDA-approved for veterinary use and is administered as an extra-label drug.
  • Always monitor treated dogs for signs of adverse reactions such as vomiting, diarrhea, lethargy, or changes in drinking and urination habits.

Dosage and Administration

  • The recommended dosage is 0.3-0.5 mg/kg intravenously or intramuscularly once daily for no more than 3 consecutive days.
  • The pharmacokinetic profile of ketorolac in dogs, as described in 1, indicates a large variability in serum concentrations, with an elimination half-life of approximately 10.95 hours.

Alternative Options

  • For longer-term pain management, veterinarians typically transition to other approved canine NSAIDs like carprofen, meloxicam, or grapiprant after the short course of ketorolac is complete.
  • The choice of alternative NSAIDs should be based on individual patient factors, such as medical history, concurrent medications, and potential side effects, as well as the specific pain management needs of the dog.

Safety and Efficacy

  • The safety and efficacy of ketorolac in dogs have been evaluated in several studies, including 1, 3, and 2, which demonstrate its effectiveness in managing postoperative pain and its relatively favorable safety profile.
  • However, as with any medication, ketorolac can cause adverse effects, and its use should be carefully monitored and managed to minimize potential risks.

References

Research

Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs.

Journal of veterinary pharmacology and therapeutics, 2013

Research

A comparison of ketorolac with flunixin, butorphanol, and oxymorphone in controlling postoperative pain in dogs.

The Canadian veterinary journal = La revue veterinaire canadienne, 1996

Research

Single-dose intravenous ketorolac for acute postoperative pain in adults.

The Cochrane database of systematic reviews, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.